Retatrutide - Top-Line Results from TRIUMPH 4
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Retatrutide - Top-Line Results from TRIUMPH 4
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
- Up to 28.7% weight loss (~71 lbs) over 68 weeks
- 75% reduction in knee pain and major improvements in physical function
- Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure
We also cover
- Common side effects and safety signals
- Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
- A reality check on Canadian availability (likely 3+ years away)
- A strong warning about illegal online sales and the risks of buying unregulated products
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
Pas encore de commentaire